PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Annu Rev Med. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2921612
NIHMSID: NIHMS223760

Molecular Diagnosis and Therapy of Kidney Cancer

Abstract

Kidney cancer is not a single disease; it is made up of a number of cancers that occur in the kidney, each with a different histology, having a different clinical course, responding differently to therapy and caused by a different gene. Understanding the genetic basis of cancer of the kidney has significant implications for diagnosis and management of this disease. The VHL gene is the gene for clear cell kidney cancer. The VHL protein forms a complex that targets the hypoxia inducible factors for ubiquitin-mediated degradation. Knowledge of this pathway has provided the foundation for the development of a number of novel therapeutic approaches that have been approved by the FDA for treatment of this disease. The MET gene is the gene for the hereditary form of type 1 papillary renal carcinoma and has been found to be mutated in a subset of sporadic type 1 papillary kidney cancers. Clinical trials are currently ongoing with agents targeting the tyrosine kinase domain of MET in sporadic and hereditary forms of papillary kidney cancer. The BHD gene is the gene for the hereditary type of chromophobe kidney cancer. The BHD gene is thought to be involved in energy and/or nutrient sensing through the AMPK and mTOR signaling pathways. Hereditary Leiomyomatosis Renal Cell Carcinoma, a hereditary form of type 2 papillary renal carcinoma, is caused by inactivation of the Krebs cycle enzyme, fumarate hydratase (fumarase, FH). Loss of FH activity has been shown to alter the degradation of hypoxia inducible factor (HIF) in a VHL-independent fashion. Knowledge of these kidney cancer gene pathways has enabled new approaches for the management of this disease and has provided the foundations for the development of targeted therapeutics for this disease.

Keywords: kidney neoplasms, VHL, MET, BHD, TSC1, TSC2, fumarate hydratase succinate dehydrogenase

Introduction

There are over 57,000 cases of kidney cancer in the United States annually and nearly 13,000 die of this disease each year.(32) Kidney cancer is the seventh most common cancer in men and the ninth most common cancer in women.(32) Unlike other genitourinary malignancies, the incidence of kidney cancer is rapidly increasing at 2.5 percent per year. The incidence of kidney cancer can only partly be explained by the increased use of imaging modalities such as MRI, computed tomography and ultrasound.(8) While there was an increased incidence for localized disease, increases were also noted for advanced disease. The mortality rate for this disease is also increasing, suggesting that the increasing incidence is not driven by increased detection of small tumors alone.(8)

Kidney cancer is not a single disease; it is made up of a number of different types of cancer that occur in the kidney; each with a different clinical course, a different histology, caused by a different gene and responding differently to therapy.(43) Patients who present with a localized kidney tumor (TNM Stage I) have a ninety-six percent five year survival. However, patients who present with advanced disease (TNM Stage IV) have only a twenty-six percent five year survival.(41) The development of novel therapeutic approaches for targeting the kidney cancer disease gene pathways has the potential to significantly improve survival for patients with advanced forms of this disease.

Identification of the Kidney Cancer Genes

In order to improve the diagnosis and management of kidney cancer and to provide the foundation for the development of better methods for diagnosis as well as targeted therapeutic approaches to this disease, families with kidney cancer were studied in order to identify the genes for this disease.

Clear cell kidney cancer: von Hippel-Lindau

von Hippel Lindau (VHL) is a hereditary cancer syndrome in which affected individuals are at risk for the development of tumors in a number of organs, including the kidney. Patients with VHL are at risk for the development of early onset, bilateral, multifocal clear cell kidney cancer. It has been estimated that VHL patients are at risk for the development of up to 600 renal tumors and 1100 cysts per kidney.(89) Historically, 35-45% of VHL patients died of metastatic kidney cancer. While removal of both kidneys should decrease the rate of metastasis; the quality of life and long-term survival would be severely impacted. Over a 20-year period an approach has been developed for the clinical management of VHL renal tumors which involves observation of small renal tumors until they reach a 3 cm size threshold. When the tumors reach 3 cm, surgical intervention involving a nephron-sparing approach with partial nephrectomy is utilized.(87, 89) After 10 years of follow-up, no patient with VHL with a renal tumor ≤ 3 cm managed in this fashion had been found to have developed metastatic disease.(25) Renal parenchymal sparing therapy with preservation of renal function with close observation for recurrence is recommended whenever possible.(13)

Identification of the VHL gene

Genetic linkage analysis was performed in VHL families to identify the clear cell kidney cancer gene. The VHL gene was identified on the short arm of chromosome 3 and mutation of this gene was found in the germline of individuals affected with von Hippel Lindau.(38) With improved detection methods mutation of the VHL gene is now found in nearly 100% of VHL families.(75)

VHL is the clear cell kidney cancer gene

When tumor tissue from patients with kidney cancer was tested for alteration of the VHL gene, mutations were detected in a high percentage of patients with clear cell kidney cancer.(20) No mutations of the VHL gene were detected in tumors from patients with papillary, chromophobe or collecting duct kidney cancer or oncocytoma. Nickerson, et al. detected mutation or methylation of the VHL gene in 91% of tumors from patients with clear cell kidney cancer.(52)

VHL gene pathway

The VHL gene protein (would it be better to say ‘VHL protein’ or ‘VHL gene product’?) forms a complex with elongin B and elongin C and Cul2.(12, 37, 58) and targets the hypoxia inducible factors, HIF1α and HIF2α, for ubiquitin mediated degradation. The hypoxia inducible factors (HIF) are transcription factors that regulate the transcription of a number of other genes such as vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), epidermal growth factor receptor (EGFR) and the glucose transporter, GLUT1. When there is normoxia, the VHL complex targets HIF for ubiquitin-mediated degradation, while during a hypoxia, the complex does not target and degrade HIF, allowing HIF to accumulate and drive the transcription of the downstream HIF-dependent genes. When there is mutation of the VHL gene in clear cell kidney cancer, either in the alpha domain that binds elongin C/B and Cul2, or in the beta domain that targets HIF for degradation,(73) HIF is not degraded and over-accumulates. The result is the increased transcription of such HIF downstream genes as VEGF, PDGF, EGFR and GLUT1.(31, 35, 45, 54, 55, 73)

Targeting the VHL gene pathway in clear cell renal carcinoma: VEGF

Bevacizumab

The first trial to target the VHL gene pathway in clear cell renal carcinoma was with bevacizumab, an anti-VEGF antibody, which was evaluated in patients with advanced clear cell renal carcinoma. In this three arm randomized trial, patients treated with high dose bevacizumab had a significantly increased progression free survival compared with those treated with placebo.(92) This was the first trial to show a clinical effect in advanced clear cell kidney cancer with an agent targeting the VHL pathway.

Sorafenib

Sorafenib is a small molecule inhibitor which targets the tyrosine kinase domain of a number of cell surface receptors, including VEGFR and PDGFR, as well as the intracellular signaling enzyme, raf kinase.(91) When Sorafenib was evaluated in a randomized phase III study as a second line agent in patients with advanced clear-cell renal cell carcinoma, there was a 10% partial response and an increase in disease free progression from 2.8 months to 5.5 months compared to placebo.(14) Final analysis of the study revealed no difference in overall survival between the sorafenib and placebo group; however, when the post-cross-over placebo survival data was censored, there was an increase in survival in the sorafenib arm.(15) Sorafenib is frequently used as a second line agent in patients who progress while on sunitinib.

Sunitinib

Sunitinib is another small molecule receptor tyrosine kinase inhibitor which has direct antitumor as well as antiangiogenic effects. This agent has activity against the vascular endothelial growth factor receptor (VEGFR), the platelet derived growth factor receptor (PDGFR) and the KIT receptor.(46) In patients with metastatic clear cell kidney cancer sunitinib has been found to have a response rate of 31%, with a progression free survival of 11 months. In a randomized phase III trial sunitinib has been shown to improve progression free survival compared to treatment with interferon (median 11 months vs. 5 months); a recent analysis of mature data from this trial also suggests that patients randomized to the sunitinib had superior overall survival (median 26.4 months vs. 21.8 months, p=0.051). Treatment with sunitinib is associated with side effects common to this class of agents, such as fatigue, hand-foot syndrome, diarrhea, hypertension and hypothyroidism.(50) Sunitinib is often used as a first line agent in patients with advanced clear cell kidney cancer.

Axitinib

Axitinib is an oral small molecule tyrosine kinase inhibitor of vascular endothelial receptors VEGFR1, VEGFR2 and VEGFR3. In a Phase II trial of Axitinib in 52 patients with advanced kidney cancer, Rixe, et al. observed a partial response in 40% (21/52), a complete response in 4% (2/52), a median time to progression of 15.7 months and a median survival of 29.9 months. Most patients treated on this study displayed some tumor shrinkage and many had been pre-treated with either IL-2 or interferon. The response profile of these patients compares favorably with those from other antiangiogenesis trials; however, 60% of patients developed diarrhea, 58% hypertension, 52% experienced fatigue, 44% reported nausea, and 37% developed hoarseness. Treatment related proteinuria was observed in 4/52 patients.(62) The approach directed at a single type of growth factor receptor has the potential to provide a strategy for precisely targeting the VHL pathway in clear cell kidney cancer while decreasing the toxicity of multikinase inhibitors.(40)

Targeting the VHL gene pathway in clear cell renal carcinoma: mTOR

Temsirolimus

The mTORC1 pathway regulates the expression and stability of HIF1α. In preclinical models, growth arrest caused by agents which target mTOR correlate with the block in translation of mRNA encoding HIF1α.(28, 77) Hudes, et al. evaluated the effect of temsirolimus, interferon or the combination of both in patients with previously untreated, poor-prognosis metastatic renal cell carcinoma. Eighty percent of the patients in this trial had clear cell kidney cancer. The response rate to temsirolimus was 8.6%, the progression free survival in the temsirolimus treated patients was 3.8 months versus 1.9 months in the interferon treated patients (p=0.0001) and the overall survival was 10.9 months in the temsirolimus treated patients versus 7.3 months in the patients treated with interferon (p=0.0069).(27)

Everolimus

Everolimus, another orally administered small molecule inhibitor of the mammalian target of rapamycin (mTOR), was evaluated in a phase III, randomized, double-blind, placebo-controlled trial in 410 patients with metastatic kidney cancer who had progressed on sunitinib or sorafenib therapy. There was a 1% response rate in the everolimus patients and a progression free survival of 4.0 months in the everolimus arm versus 1.9 months in the placebo arm. The overall survival in the placebo arm was 8.8 months; median overall survival in the everolimus patients had not been reached.(48) Everolimus may be considered in patients who have failed VEGF-targeted agents (Figure 1).

Figure 1
Targeting the VHL gene pathway in clear cell kidney cancer

Combinations of Agents Targeting the VHL Pathway

Trials are currently under way to evaluate the role of combinations of therapeutic agents which target the VHL pathway(17, 49, 57) as well as the role of sequential therapy in kidney cancer. The combined toxicity of targeted agents can be significant and dose reduction is often required. While there is evidence that administering targeted agents sequentially provides clinical benefit and prolongs progression-free survival, data on overall survival awaits the results of trials currently in progress.(16)

Targeting the VHL pathway: neoadjuvant (presurgical) therapy for clear cell kidney cancer

The standard of care for patients with metastatic kidney cancer has been cytoreductive nephrectomy prior to administration of systemic therapy.(18, 86) The clinical approach involves an assessment of the patient's clinical condition and the extent of the metastatic disease. In general, at the National Cancer Institute, if a patient has more disease in the kidney than outside the kidney, cytoreductive nephrectomy followed by systemic therapy is recommended. If the patient has more disease outside the kidney or has rapidly progressive disease, initial systemic therapy is recommended.(85) This approach has largely been extended to studies involving targeted therapeutics, where the majority of patients on clinical trials have previously had a cytoreductive nephrectomy.

While there are no completed randomized prospective studies addressing the role of the neoadjuvant therapy in setting of metastatic RCC, a few retrospective series have described the use of neoadjuvant targeted therapy in patients with their primary kidney tumor in place. Van der Veldt, et al observed a partial response in 4/17 patients who had been treated with sunitinib prior to cytoreductive nephrectomy. There was a 31% volume reduction in the primary tumor of responding patients.(82) Shuch, et al. reported on four patients who were given neoadjuvant targeted therapy. These patients had shrinkage of tumor thrombus in the inferior vena cava, in retroperitoneal nodes and in a renal fossa recurrence.(70) Karakiewicz et al. reported a dramatic down-staging of a thrombus in the right atrium in a 75 year old woman treated with two cycles of sunitinib.(36)

Margulis, et al. evaluated the surgical parameters and perioperative complications of 44 patients treated with targeted molecular therapies before either cytoreductive nephrectomy or resection of renal cell carcinoma recurrence with a matched cohort of patients with metastatic kidney cancer who had up front cytoreductive nephrectomy. They found no significant difference between the incidence of perioperative mortality, re-exploration, cardiovascular, thromboembolic or other surgical complications between the two groups.(44) Potential advantages of neoadjuvant therapy include tumor downsizing and early institution of systemic therapy, as well as identification of those patients who do not respond to therapy and could be spared a morbidity of a cytoreductive nephrectomy. Alternatively, it is possible that patients who undergo cytoreductive nephrectomy up front will respond better to therapy than those who receive neoadjuvant therapy, followed by cytoreductive nephrectomy and subsequent resumption of systemic therapy. Controlled trials will determine the role of neoadjuvant therapy in the setting of metastatic kidney cancer in patients with their primary kidney cancer in place.

Targeting the VHL pathway: adjuvant therapy for clear cell kidney cancer

The 5 year survival rate for patients who present with locally advanced kidney cancer (TNM Stage III) is 40 to 60% and 20 to 40% of patients who undergo surgical resection for clinically localized disease will experience either a local or systemic recurrence.(22) The advent of a number of novel targeted molecular therapeutic approaches in the treatment of clear cell kidney cancer raises the possibility that adjuvant therapy may be beneficial for patients with high risk/locally advanced kidney cancer who have undergone complete surgical resection. A number of clinical trials are underway to determine whether or not adjuvant targeted therapy will be beneficial to patients with high risk localized or locally advanced kidney cancer. The ECOG intergroup trial (ASSURE) randomizes patients with clear and non-clear cell kidney cancer to receive either 1 year of sunitinib, sorafenib or placebo. The MRC trial (SORCE) randomizes patients with clear and non-clear cell kidney cancer to receive either placebo (3 years) or sorafenib (1-3 years). The Pfizer trial (S-TRAC) randomizes patients with clear cell kidney cancer to receive sunitinib versus placebo for 1 year. The Wilex trial (ARISER) randomizes patients to receive G250 monoclonal chimeric antibody versus placebo.

Imaging the VHL Pathway

Carbonic Anhydrase 9 (CA9) is Regulated by VHL

In 1998 investigators in the laboratory of Michael Lerman at the National Cancer Institute, using RNA differential display to study genes in the VHL pathway, found that the carbonic anhydrase genes, CA9 and CA12, were regulated by the VHL protein. Mutation of the VHL gene was found to up-regulate these transmembrane enzymes which are critical for the regulation of pH in the extracellular microenvironment.(30) Kaluz et al. recently reported that carbonic anhydrase 9 is tightly regulated by the transcriptional activity of HIF1α and is one of the most sensitive endogenous sensors of its activity.(34)

Functional Imaging with G250, an Antibody that Recognizes CA9

G250, an antibody that has high binding affinity for clear cell kidney cancer(74), has been shown to recognize the epitope of carbonic anhydrase 9.(81) Bui et al. showed that CA9 expression is found in more than 94% of clear cell kidney cancers.(5, 6, 81) Divgi et al. conducted a study using an 124I-labelled chimeric G250 antibody (124I-cG250) to perform pre-operative characterization of clear cell kidney cancer and accurately identified 15 of 16 clear cell kidney cancers by 124I-cG250 PET scanning. This study clearly delineated clear cell renal carcinoma from other types of kidney tumors and provides a potential alternative to tumor biopsy.(11) This technique provides a potential molecular diagnostic to differentiate tumors with VHL gene mutations from other types of kidney cancer.

Type I Papillary Renal Carcinoma: Hereditary Papillary Renal Carcinoma

Hereditary Papillary Renal Carcinoma (HPRC) is an inherited cancer syndrome in which affected individuals are at risk for the development of bilateral, multifocal type 1 papillary renal carcinoma.(94) Genetic linkage was performed in HPRC families and the MET gene on chromosome 7 was found to be the HPRC gene.(65) Activating mutations in the tyrosine kinase domain of MET are found in the germline of affected individuals in HPRC families. The renal tumors in HPRC patients are highly penetrant, and it is estimated that an HPRC patient who lives to 80 has a nearly 90% likelihood of developing kidney cancer.(67) These individuals are at risk for the development of up to 3400 microscopic papillary tumors per kidney.(56) The management approach for HPRC patients is similar to that in VHL patients; active surveillance is recommended until the largest tumor reaches the 3 cm threshold.(7, 25)

Targeting the MET gene pathway in type 1 papillary kidney cancer

A multicenter Phase II clinical trial is currently underway evaluating the role of GSK'089 (foretinib), an oral dual kinase small molecule agent which targets the tyrosine kinase domains of MET as well as VEGFR2, in patients with sporadic as well as hereditary papillary kidney cancer. Activity has been observed with this agent in papillary RCC, notably in tumors with MET mutations (Figure 2).(71)

Figure 2
Targeting the MET gene pathway in type 1 papillary kidney cancer

Chromophobe Kidney Cancer: Birt-Hogg-Dubé

Birt-Hogg-Dubé (BHD) is an inherited cancer syndrome in which affected individuals are at risk for the development of benign cutaneous lesions (fibrofolliculomas), pulmonary cysts and renal tumors.(93) BHD patients are at risk for the development of bilateral, multifocal chromophobe, hybrid oncocytic and clear cell renal cell carcinomas and oncocytomas.(59) Genetic linkage analysis was performed in BHD kindreds to identify the BHD gene on chromosome 17.(53) Germline BHD gene mutations have been found in over 90% of BHD kindreds.(68, 80) The BHD gene has the classic characteristics of a loss of function, tumor suppressor gene.(84)

Targeting the BHD pathway in chromophobe kidney cancer

The product of the BHD gene, folliculin (FLCN), forms a complex with two FLCN interacting proteins, FNIP1 and FNIP2, which bind AMPK, a key molecule for energy sensing that negatively regulates mTOR activity.(2, 23) The BHD gene is thought to be involved in energy sensing through the AMPK and mTOR pathways.

In order to develop a model to evaluate agents which target the BHD pathway, a mouse model was developed in which the BHD gene was selectively knocked out in the kidneys. Affected mice developed enlarged, polycystic kidneys and died from renal failure by 3 weeks of age. Rapamycin treated mice had significantly smaller kidneys than control animals and their life-expectancy was nearly doubled.(1) These findings may provide a rationale for the development of a targeted approach to BHD-associated chromophobe as well as sporadic chromophobe kidney cancer.

Type 2 papillary kidney cancer: Hereditary Leiomyomatosis Renal Cell Carcinoma

Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC) is an inherited cancer syndrome in which affected individuals are at risk for the development of uterine and cutaneous leiomyomas and kidney cancer.(39) HLRCC-associated kidney cancer is an unusually aggressive type of kidney cancer that has a propensity to spread, even when the primary kidney tumor is very small.(21, 47) Surveillance is not recommended in HLRCC kidney cancer; early surgical resection is recommended when an HLRCC renal tumor is detected.

Targeting the fumarate hydratase gene in type 2 papillary kidney cancer

The Krebs cycle enzyme, fumarate hydratase, is the gene for HLRCC.(78) Mutations of the fumarate hydratase gene are found in over 90% of HLRCC families.(79, 90) Isaacs, et al. showed that when fumarate hydratase is inactivated, increased levels of fumarate act as a competitive inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase. This prevents HIF hydroxylation and results in a VHL-independent mechanism for decreased degradation of HIF.(29) A more recent study has reinforced the glycolytic nature of HLRCC and has identified accumulation of reactive oxygen species as an additional determinant of HIF stabilization.(76) These observations provide the basis for potential therapeutic approaches targeting the HIF pathway and HIF-dependent glycolysis for HLRCC-associated renal cancers.

SDHB germline mutations and familial renal cancer

Succinate dehydrogenase is another Krebs cycle enzyme gene that has been associated with the development of familial tumors. Familial paraganglioma/pheochromocytoma kindreds have been found to have germline mutations in the mitochondrial complex II genes, SDHB, SDHC, and SDHB. Renal carcinoma, along with pheochromocytoma/paraganglioma, has been found to be a component of the familial pheochromocytoma/paraganglioma complex(24, 51, 72, 83) and a recent report described germline SDHB mutations in a family with renal cancer with no history of pheochromocytoma.(61)

Tuberous Sclerosis

The tuberous sclerosis complex is an autosomal dominant disorder associated with mutation of either the TSC1 or TSC2 gene. Affected individuals are at risk for the development of a number of neurologic, dermatologic and pulmonary manifestations as well as renal angiomyolipomas.(9) The TSC1-TSC2 complex interacts with a number of cellular pathways, including modulation of mTOR. When the cell senses energy deprivation, AMPK activates TSC2 and mTOR activity is decreased.(9)

Renal angiomyolipomas are most often managed conservatively. Angioinfarction is often recommended for tumors over 4 cm in size, although surgical resection may also be performed if there is concern about imminent hemorrhage or if renal angiomyolipoma is found in young women of child-bearing age.(69)

Targeting the mTOR pathway in tuberous sclerosis

Bissler, et al. evaluated the role of sirolimus, an agent which targets the mTOR pathway, in patients affected with tuberous sclerosis and lymphangioleiomyomatosis. In this trial, the renal angiomyolipomas regressed during sirolimus therapy, however, they tended to increase in size after the treatment was stopped.(3)

Management of small renal masses: lessons learned from management of tumors with known genetic alterations

Nephrectomy versus Partial Nephrectomy

Hereditary Tumors

Since the mid 1980's the management of small renal masses in patients with VHL, HPRC and BHD has involved observation until the largest mass reaches 3 centimeters. As these patients are at risk for the development of bilateral, multifocal tumors, the use of parenchymal sparing surgery was based on a desire to maintain renal function as long as possible while reducing the risk for metastasis.(87, 88) Using this approach, no patient who underwent renal parenchymal sparing surgery required renal replacement and no patient whose tumor ≤ 3 cm was removed was found to have developed metastasis at 10 years.(25)

Over the years organ preservation was combined with minimally invasive techniques. Laparoscopic and then robotic partial nephrectomy was found to provide minimally invasive and nephron sparing surgical options for patients who might otherwise require open surgery or total nephrectomy.(4, 63, 64)

Sporadic Tumors

The same techniques developed for patients with inherited, bilateral multifocal renal tumors have been applied to patients with sporadic, non-inherited renal tumors. Gill et al. reported a series of 1800 patients who underwent either open or laparoscopic partial nephrectomy. With either technique, there was excellent functional and oncologic outcome.(19) Huang, et al. recently reviewed the SEER cancer registry database and highlighted the increased cardiovascular morbidity associated with nephrectomy versus partial nephrectomy and recommend partial versus total nephrectomy whenever feasible.(26)

Management of small sporadic renal tumors: intervention or surveillance

A surveillance approach for the management of small renal tumors in patients with VHL, hereditary papillary renal carcinoma (HPRC) and Birt-Hogg-Dubé (BHD) was adopted in the 1980's. Patients with VHL (clear cell RCC), HPRC (type 1 papillary RCC) or BHD (chromophobe or hybrid oncocytic RCC) were managed expectantly when the largest renal tumor was less than 3 cm in size. When the largest tumor reached 3 cm, surgical intervention was recommended. This approach was found to be safe and preserved renal function over a 20-year period. Active surveillance is not recommended in patients with hereditary leiomyomatosis renal cell cancer (HLRCC), who develop aggressive type 2 papillary renal cancers. In these patients early surgical intervention is recommended.

A rational for surveillance of sporadic renal tumors comes from the experience with management of hereditary renal tumors with known genetic alterations. The biologic behavior of a hereditary renal tumor with a known genetic alteration should be no different from a sporadic renal tumor with a mutation of the same gene. A clear cell renal carcinoma in a patient affected with VHL has a mutation of the VHL gene as well as loss of the second allele (i.e., biallelic inactivation of the VHL gene). A sporadic clear cell renal tumor with a VHL mutation has loss of the second allele as well (i.e., biallelic inactivation of the VHL gene). The histology of the VHL clear cell renal tumor and the histology of the sporadic clear cell renal tumor with a VHL gene mutation are identical.

There have been a number of reports on the role of active surveillance (AS) for clinically localized renal masses.(10, 33) Crispen reported on 172 renal tumors with a median tumor diameter of 2.0 cm in 154 patients under AS. Thirty-nine percent of the tumors underwent delayed intervention and 84% were found to be pathologically malignant. Metastatic disease developed in 2/154 (1.3%) patients.(10) Metastatic disease was also detected in 2% of the patients on active surveillance in the Canadian prospective trial.(33)

A renal biopsy is now increasingly accepted for patients being considered for active surveillance. Although some renal tumors will be found to be benign, some will be high grade malignant tumors (type 2 papillary, collecting duct or medullary RCC) that are not suitable for surveillance. Active surveillance is an appropriate option for selected patients who are elderly or those with significant comorbidities. For example. in a well selected elderly or frail patient with low grade clear cell renal carcinoma, active surveillance might be an appropriate option. In contrast, presence of a high grade type 2 papillary renal carcinoma should warrant intervention, as delay in treatment may not be justified. Further studies will be required to determine whether active surveillance with delayed surgical management is a safe alternative to surgical resection in younger patients.

Kidney cancer is fundamentally a metabolic disorder

Understanding the kidney cancer gene pathways has provided the foundation for the development of targeted therapeutic approaches for this disease. Knowledge of the genetic basis of kidney cancer has important implications for diagnosis and management of this disease.

Study of the genes for kidney cancer has revealed that kidney cancer is fundamentally a metabolic disorder. The seven kidney cancer genes represent disorders of energy, nutrient, iron and oxygen sensing (Figure 3). Although current approaches of targeting the downstream HIF upregulated genes has resulted in dramatic response to therapy and increased survival, few complete responses have been reported and most patients progress to succumb to the disease. Targeting the basic metabolic alterations in kidney cancer has the potential to provide a more durable and effective approach to therapy.

Figure 3
Kidney cancer is fundamentally a metabolic disorder

Summary Points

  1. Clear cell kidney cancer and kidney cancer associated with von Hippel-Lindau are caused by mutation of the VHL gene, which results in a disorder of oxygen sensing.
  2. Hereditary papillary renal cell carcinoma and a subset of sporadic type 1 papillary kidney cancers are caused by mutation of the MET gene.
  3. The hereditary form of chromophobe kidney cancer associated with Birt-Hogg-Dubé is caused by mutation of the BHD gene, which is involved with the AMPK/mTOR pathway.
  4. The hereditary form of kidney cancer associated with Hereditary Leiomyomatosis Renal Cell Carcinoma is caused by mutation of the gene for the Krebs cycle enzyme, fumarate hydratase.
  5. The hereditary form of kidney cancer associated with familial pheochromocytoma/paraganglioma results from mutations of the gene for the Krebs cycle enzyme, succinate dehydrogenase B.
  6. The hereditary form of angiomyolipoma results from mutations of the TSC1 and TSC2 genes, which are involved in the AMPK/mTOR pathway.
  7. Understanding the pathways of the kidney cancer genes has provided the foundation for the development of targeted therapeutic approaches to the treatment of these diseases.
Table 1
Targeting the Kidney Cancer Genes

Supplementary Material

Fig Legends

Acknowledgments

This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Heath and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

The authors acknowledge the outstanding editorial and/or graphics support by Georgia Shaw and Masaya Baba, M.D., Ph.D.

Footnotes

Disclosure Statement: The authors have no conflicts of interest to disclose.

Literature Cited

1. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. 2008;100:140–54. [PMC free article] [PubMed]
2. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006;103:15552–7. [PubMed]
3. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51. [PMC free article] [PubMed]
4. Boris R, Proano M, Linehan WM, et al. Robotic assisted partial nephrectomy for multiple renal masses: feasibility and results of initial experience. J Urol. 2009 In Press. [PMC free article] [PubMed]
5. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–11. [PubMed]
6. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461–6. [PubMed]
7. Chernoff A, Choyke PL, Linehan WM, et al. Parenchymal sparing surgery in a patient with multiple bilateral papillary renal cancer. J Urol. 2001;165:1623–4. [PubMed]
8. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–31. [PubMed]
9. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–56. [PubMed]
10. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009 Epub. [PMC free article] [PubMed]
11. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10. [PubMed]
12. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science. 1995;269:1402–6. [PubMed]
13. Duffey BG, Choyke PL, Glenn GM, et al. The Relationship Between Renal Tumor Size and Metastases in Patients with von Hippel-Lindau Disease. J Urol. 2004;172:63–5. [PubMed]
14. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34. [PubMed]
15. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol 2009 [PubMed]
16. Escudier B, Goupil MG, Massard C, et al. Sequential therapy in renal cell carcinoma. Cancer. 2009;115:2321–6. [PubMed]
17. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–9. [PubMed]
18. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9. [PubMed]
19. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol. 2007;178:41–6. [PubMed]
20. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genetics. 1994;7:85–90. [PubMed]
21. Grubb RL, III, Franks ME, Toro J, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177:2074–80. [PubMed]
22. Haas NB, Uzzo R. Adjuvant therapy for renal cell carcinoma. Curr Oncol Rep. 2008;10:245–52. [PubMed]
23. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene. 2008;415:60–7. [PMC free article] [PubMed]
24. Henderson A, Douglas F, Perros P, et al. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. Fam Cancer 2009 [PubMed]
25. Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol. 2001;165:777–81. [PubMed]
26. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181:55–61. [PMC free article] [PubMed]
27. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81. [PubMed]
28. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004–14. [PMC free article] [PubMed]
29. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143–53. [PubMed]
30. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A. 1998;95:12596–601. [PubMed]
31. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–72. [PubMed]
32. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA: A Cancer Journal for Clinicianscaac 2009 [PubMed]
33. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35:627–34. [PubMed]
34. Kaluz S, Kaluzova M, Liao SY, et al. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta. 2009;1795:162–72. [PMC free article] [PubMed]
35. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999;284:657–61. [PubMed]
36. Karakiewicz PI, Suardi N, Jeldres C, et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol. 2008;53:845–8. [PubMed]
37. Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995;269:1444–6. [PubMed]
38. Latif F, Tory K, Gnarra JR, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20. [PubMed]
39. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A. 2001;98:3387–2. [PubMed]
40. Linehan WM. Targeting VEGF receptors in kidney cancer. Lancet Oncol. 2007;8:956–7. [PubMed]
41. Linehan WM, Bates SE, Yang JC. Cancer of the Kidney. In: DeVita SE, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th. Philadelphia: Lippincott Williams & Wilkins; 2005. pp. 1139–1168.
42. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13:671s–9s. [PubMed]
43. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–72. [PubMed]
44. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94–8. [PubMed]
45. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–5. [PubMed]
46. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37. [PubMed]
47. Merino MJ, Torres-Cabala CA, Zbar B, et al. Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC); Clinical, Histopathological and Molecular Features of the First American Families Described. Mod Pathol. 2003;16:739.
48. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 [PubMed]
49. Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7:28–33. [PMC free article] [PubMed]
50. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. [PubMed]
51. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–51. [PubMed]
52. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14:4726–34. [PMC free article] [PubMed]
53. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157–64. [PubMed]
54. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423–7. [PubMed]
55. Ohh M, Takagi Y, Aso T, et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999;104:1583–91. [PMC free article] [PubMed]
56. Ornstein DK, Lubensky IA, Venzon D, et al. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol. 2000;163:431–3. [PubMed]
57. Patel PH, Senico PL, Curiel RE, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2009;7:24–7. [PubMed]
58. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997;94:2156–61. [PubMed]
59. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26:1542–52. [PubMed]
60. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8:779–90. [PMC free article] [PubMed]
61. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100:1260–2. [PubMed]
62. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007 [PubMed]
63. Rogers CG, Metwalli A, Blatt AM, et al. Robotic partial nephrectomy for renal hilar tumors: a multi-institutional analysis. J Urol. 2008;180:2353–6. [PMC free article] [PubMed]
64. Rogers CG, Singh A, Blatt AM, et al. Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol. 2008;53:514–21. [PMC free article] [PubMed]
65. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics. 1997;16:68–73. [PubMed]
66. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–50. [PubMed]
67. Schmidt L, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 1998;58:1719–22. [PubMed]
68. Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet. 2005;76:1023–33. [PubMed]
69. Seyam RM, Bissada NK, Kattan SA, et al. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. Urol. 2008;72:1077–82. [PubMed]
70. Shuch B, Riggs SB, LaRochelle JC, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008;102:692–6. [PubMed]
71. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) Journal of Clinical Oncology. 2008;26(May 20 Suppl):5103.
72. Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) 2008;69:587–96. [PubMed]
73. Stebbins CE, Kaelin WG, Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999;284:455–61. [PubMed]
74. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529–37. [PubMed]
75. Stolle C, Glenn GM, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417–23. [PubMed]
76. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1{alpha} stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009 [PMC free article] [PubMed]
77. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122–7. [PubMed]
78. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–10. [PubMed]
79. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95–106. [PubMed]
80. Toro JR, Pautler SE, Stewart L, et al. Lung Cysts, Spontaneous Pneumothrorax and Genetic Associations in 89 Families with Birt-Hogg-Dube Syndrome. Am J Respir Crit Care Med. 2007;175:1044–53. [PMC free article] [PubMed]
81. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741–6. [PMC free article] [PubMed]
82. van d V, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431–6. [PubMed]
83. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet. 2004;74:153–9. [PubMed]
84. Vocke CD, Yang Y, Pavlovich CP, et al. High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-Dube-Associated Renal Tumors. J Natl Cancer Inst. 2005;97:931–5. [PubMed]
85. Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162:43–5. [PubMed]
86. Walther MM, Alexander RB, Weiss GI, et al. Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urol. 1993;42:250–8. [PubMed]
87. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161:1475–9. [PubMed]
88. Walther MM, Choyke PL, Weiss G, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153:913–6. [PubMed]
89. Walther MM, Lubensky IA, Venzon D, et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol. 1995;154:2010–4. [PubMed]
90. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43:18–27. [PMC free article] [PubMed]
91. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–40. [PubMed]
92. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–34. [PMC free article] [PubMed]
93. Zbar B, Alvord WG, Glenn GM, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393–400. [PubMed]
94. Zbar B, Tory K, Merino MJ, et al. Hereditary papillary renal cell carcinoma. J Urol. 1994;151:561–6. [PubMed]